ArticleBlood2007
The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.
Article in Blood, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for theFrontiers in immunology · 2018Pooled it
- Review
- Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients.Blood advances · 2026Article
- Stem-like memory-T maintenance and differentiation into tissue-resident T cells sustain chronic graft-versus-host disease in mice.Nature communications · 2026Article
- Association of Donor and Recipient Duffy and Kidd Genotypes with GVHD in Leukemia Patients Undergoing Bone Marrow Transplantation.Iranian journal of pathology · 2026Article
- Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in Adults.American journal of hematology · 2025Article
- Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion.Annals of hematology · 2025Article
- Tolerance in intestinal transplantation.Human immunology · 2024Review
- Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies.Experimental hematology & oncology · 2024Review
- The function of the complement system remains fully intact throughout the course of allogeneic stem cell transplantation.Frontiers in immunology · 2024Article
- Monocytes as an early risk factor for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2024Article
- Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection.JCI insight · 2023Article
- Defining a TCF1-expressing progenitor allogeneic CD8Nature communications · 2023Article
- PD-L1's Role in Preventing Alloreactive T Cell Responses Following Hematopoietic and Organ Transplant.Cells · 2023Review
- Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease.Blood advances · 2023Article
- The chemerin/CMKLR1 axis regulates intestinal graft-versus-host disease.JCI insight · 2023Article
- Graft-versus-Host Disease Modulation by Innate T Cells.International journal of molecular sciences · 2023Review
- The Absence of IL-12Rβ2 Expression on Recipient Nonhematopoietic Cells Diminishes Acute Graft-versus-Host Disease in the Gastrointestinal Tract.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.Frontiers in immunology · 2023Article
- Complex interactions of cellular players in chronic Graft-versus-Host Disease.Frontiers in immunology · 2023Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
After allogeneic blood or bone marrow transplantation, donor T cells interact with a distorted antigen-presenting cell (APC) environment in which some, but not all, host APCs are replaced by APCs from the donor. Significantly, host APCs are required for the priming of acute graft-versus-host disease (GVHD). Donor APCs play a lesser role in the induction of acute GVHD despite their predicted capacity to cross-present host antigens. In contrast, donor APCs may play a role in perpetuating the tissue injury observed in chronic GVHD. Host APCs are also required for maximal graft-versus-leukemia responses. Recent studies have suggested potential strategies by which the continued presence of host APCs can be exploited to prime strong donor immunity to tumors without the induction of GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.